View in EDS PDF Full Text

ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.

Saved in:
Bibliographic Details
Title: ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
Authors: Koneru B; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Farooqi A; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Nguyen TH; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Chen WH; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Hindle A; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Eslinger C; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Makena MR; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Burrow TA; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA., Wilson J; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Smith A; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Pilla Reddy V; Clinical Pharmacology and Quantitative Pharmacology, Biopharmaceuticals R&D, AstraZeneca, Cambridge SG8 6EE, UK., Cadogan E; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Durant ST; Early Oncology, R&D AstraZeneca, Cambridge CB10 1XL, UK., Reynolds CP; Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA. patrick.reynolds@ttuhsc.edu.; Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.; Department of Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Source: Science translational medicine [Sci Transl Med] 2021 Aug 18; Vol. 13 (607).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1946-6242
DOI:10.1126/scitranslmed.abd5750